Apelin Receptor Blocking Peptide is synthetically produced from the 150-200 sequence and is suitable for use in western blot applications.
Applications
Immunodepletion/Immunocompetition
Note
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Product Properties
Formulation
Liquid form at 2.5mg/ml concentration in PBS. Up to 5% DMSO can be added. Orders with >1mg can be supplied in lyophilized powder form, or in buffer of choice.
Storage Instruction
Store at-20°C for long term storage. Avoid freeze-thaw cycles.
Synthetic peptide taken within amino acid region 150-200 human Apelin receptor protein.
Immunogen Region
150-200
Additional Info
Tissue Specificity
Expressed in heart, brain, kidney, stomach, spleen, thymus, lung, ovary, small intestine and colon, adipose tissues and pancreas. Expressed in glial cells, astrocytes and neuronal subpopulations. Expressed in embryonic (ESCs) and induced (iPSCs) pluripotent stem cells.
Function
Receptor for apelin receptor early endogenous ligand (APELA) and apelin (APLN) hormones coupled to G proteins that inhibit adenylate cyclase activity. Plays a key role in early development such as gastrulation, blood vessels formation and heart morphogenesis by acting as a receptor for APELA hormone. May promote angioblast migration toward the embryonic midline, i.e. the position of the future vessel formation, during vasculogenesis. Promotes sinus venosus (SV)-derived endothelial cells migration into the developing heart to promote coronary blood vessel development. Also plays a role in various processes in adults such as regulation of blood vessel formation, blood pressure, heart contractility and heart failure. (Microbial infection) Alternative coreceptor with CD4 for HIV-1 infection.may be involved in the development of AIDS dementia.
Cell MembraneAfter Exposure To Apelin (Apln)Internalized From The Cell Surface Into An Endosomal Recycling CompartmentFrom Where It Is Recycled To The Cell MembraneAfter Exposure To Apelin Receptor Early Endogenous Ligand (Apela)
